 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies NYSE: SQZ, a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that the companys Investigational New Drug IND application for SQZTM Activating Antigen Carriers SQZ AACs in HPV tumors was cleared by the U.S. Food and Drug Administration FDA. The clinical trial will investigate SQZ-AAC-HPV, a cell therapy candidate generated from red blood cells RBCs engineered with tumor-specific ant 